Department of Health and Social Care (DHSC) has issued a medicine supply notification for Prochlorperazine (Stemetil®) 5mg/5ml Syrup.

MSN/2022/085

Tier 2 – medium impact

Date of issue 12th October 2022

All batches of Stemetil 5mg/5ml Syrup have been recalled as a precautionary measure due to the identification of N-nitrosomethylphenylamine (NMPA) above the acceptable limit.
A recall notice has been issued by the Medicine and Healthcare products Regulatory Agency: Class 2 Medicines Recall: Aventis Pharma Limited (t/a Sanofi), Stemetil 5mg/5ml Syrup.
There will be no further production of Stemetil 5mg/5ml Syrup, so this is in effect a product discontinuation and supplies are no longer available.
Prochlorperazine tablets and buccal tablets remain available and can support a full uplift in demand.
Alternative antiemetics are also available and can support a full uplift in demand.

A copy of this medicine supply notification, including further information, has been sent to all pharmacy NHS email addresses.

DHSC and NHSE/I have now launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues. The contents of these MSNs can now be viewed on the Tool.

The Tool also details any changes to resupply dates and updates to the entries.

To access the Tool you will need  an NHS email address. Once set up and logged in, you will be able to access it online.

New shortages not listed on the SPS website, can be reported using our shortage reporting tool.

The post Medicine Supply Notification: Prochlorperazine (Stemetil®) 5mg/5ml Syrup appeared first on PSNC Website.